Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Multiple Myeloma 155Leukemia, Lymphocytic, Chronic, B-Cell 43Lymphoma, Large B-Cell, Diffuse 26Lymphoma 25Lymphoma, Non-Hodgkin 23Lymphoma, Mantle-Cell 23Lymphoma, Follicular 23Leukemia 22Recurrence 21Neoplasms, Plasma Cell 19Myelodysplastic Syndromes 12Lymphoma, B-Cell, Marginal Zone 12Leukemia, Myeloid, Acute 12Waldenstrom Macroglobulinemia 8Smoldering Multiple Myeloma 8Hodgkin Disease 8Prostatic Neoplasms 7Lymphoma, B-Cell 6Lymphoma, T-Cell 5Lymphoma, Large-Cell, Anaplastic 5Hematologic Diseases 5Sezary Syndrome 4Mycosis Fungoides 4Lymphoma, T-Cell, Peripheral 4Leukemia, Myelomonocytic, Chronic 4Immunoblastic Lymphadenopathy 4Anemia 4Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Polycythemia Vera 3Lymphoma, T-Cell, Cutaneous 3

Interventions

Cyclophosphamide 4Prednisone 3Doxorubicin 3prednylidene 2deltacortene 2Vorinostat 2Vincristine 2Etoposide 2Brentuximab Vedotin 2pembrolizumab 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1Receptors, Chimeric Antigen 1Peripheral Blood Stem Cell Transplantation 1Nivolumab 1MLN 8237 1Lenalidomide 1Ki-1 Antigen 1Bortezomib 1Automobiles 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Enteropathy-Associated T-Cell Lymphoma × Lenalidomide × Clear all
NCT02561273 2023-12-13

Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma

University of Nebraska

Phase 1/2 Completed
54 enrolled 14 charts
Lymphoid

Immunoblastic Lymphadenopathy, Lymphoma, T-Cell, Lymphoma, Large-Cell, Anaplastic, Enteropathy-Associated T-Cell Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡